OTCMKTS:IPSEY - Ipsen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$24.10
▲ +0.57 (2.42%)

This chart shows the closing price for IPSEY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ipsen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSEY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSEY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Ipsen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $24.10.

This chart shows the closing price for IPSEY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Ipsen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/11/2022UBS GroupUpgradeNeutral ➝ Buy
1/6/2022Societe GeneraleUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/24/2021Berenberg BankInitiated CoverageHold
11/5/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
10/22/2021Credit Suisse GroupReiterated RatingNeutral
10/19/2021Exane BNP ParibasInitiated CoverageNeutral
10/19/2021BarclaysDowngradeOverweight ➝ Underweight
10/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/7/2021Morgan StanleyReiterated RatingEqual Weight
8/16/2021Morgan StanleyReiterated RatingEqual Weight
8/3/2021Morgan StanleyReiterated RatingEqual Weight
8/2/2021Societe GeneraleReiterated RatingHold
7/30/2021Credit Suisse GroupReiterated RatingNeutral
6/29/2021Societe GeneraleReiterated RatingHold
6/14/2021Societe GeneraleDowngradeBuy ➝ Hold
5/28/2021BarclaysReiterated RatingOverweight
5/27/2021JPMorgan Chase & Co.Reiterated RatingOverweight
4/23/2021Societe GeneraleReiterated RatingBuy
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
2/16/2021BarclaysReiterated RatingOverweight
1/14/2021Societe GeneraleUpgradeHold ➝ Buy
12/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
12/4/2020Bank of AmericaDowngradeBuy ➝ Neutral
12/2/2020Bryan, Garnier & CoDowngradeBuy ➝ Neutral
10/26/2020BarclaysUpgradeEqual Weight ➝ Overweight
9/1/2020Morgan StanleyReiterated RatingOverweight
8/4/2020UBS GroupReiterated RatingBuy
8/3/2020Credit Suisse GroupReiterated RatingNeutral
7/31/2020BarclaysReiterated RatingEqual Weight
7/22/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
7/16/2020Societe GeneraleDowngradeBuy ➝ Hold
7/14/2020Morgan StanleyReiterated RatingOverweight
6/1/2020BarclaysReiterated RatingEqual Weight
6/1/2020Bank of AmericaUpgradeNeutral ➝ Buy
5/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/22/2020UBS GroupReiterated RatingBuy
4/20/2020BarclaysReiterated RatingEqual Weight
2/11/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral
1/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
1/5/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/9/2019BarclaysDowngradeOverweight ➝ Equal Weight
5/20/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
2/19/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
10/29/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform
10/8/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
9/28/2018The Goldman Sachs GroupInitiated CoverageSell
9/20/2017Societe GeneraleUpgradeHold ➝ Buy
9/19/2017Societe GeneraleUpgradeHold ➝ Buy
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Ipsen logo
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults an
Read More

Today's Range

Now: $24.10
Low: $24.03
High: $24.10

50 Day Range

MA: $24.11
Low: $21.71
High: $26.30

52 Week Range

Now: $24.10
Low: $19.35
High: $28.10

Volume

1,220 shs

Average Volume

1,901 shs

Market Capitalization

$8.08 billion

P/E Ratio

N/A

Dividend Yield

0.81%

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Ipsen?

The following sell-side analysts have issued stock ratings on Ipsen in the last twelve months: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Exane BNP Paribas, JPMorgan Chase & Co., Morgan Stanley, Societe Generale, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for IPSEY.

What is the current price target for Ipsen?

0 Wall Street analysts have set twelve-month price targets for Ipsen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ipsen in the next year.
View the latest price targets for IPSEY.

What is the current consensus analyst rating for Ipsen?

Ipsen currently has 2 sell ratings, 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IPSEY, but not buy more shares or sell existing shares.
View the latest ratings for IPSEY.

How do I contact Ipsen's investor relations team?

Ipsen's physical mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company's listed phone number is (315) 833-5000 and its investor relations email address is [email protected] The official website for Ipsen is www.ipsen.com.